Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Bartter syndrome type 1 Indication Strategy Report 2026: SLC12A1, Trials and Deals
30 July 2026
2026 Bartter syndrome type 1 indication strategy covering epidemiology, SLC12A1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Tip lesion focal segmental glomerulosclerosis Indication Strategy Report 2026: APOL1, Trials and Deals
30 July 2026
2026 Tip lesion focal segmental glomerulosclerosis indication strategy covering epidemiology, APOL1 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Renal hypouricemia Indication Strategy Report 2026: SLC22A12, Trials and Deals
30 July 2026
2026 Renal hypouricemia indication strategy covering epidemiology, SLC22A12 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Antiglomerular basement membrane disease Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Antiglomerular basement membrane disease indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
C3 glomerulonephritis Indication Strategy Report 2026: C3, Trials and Deals
30 July 2026
2026 C3 glomerulonephritis indication strategy covering epidemiology, C3 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Shiga toxin-associated hemolytic uremic syndrome Indication Strategy Report 2026: C5, Trials and Deals
30 July 2026
2026 Shiga toxin-associated hemolytic uremic syndrome indication strategy covering epidemiology, C5 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Fibronectin glomerulopathy Indication Strategy Report 2026: FN1, Trials and Deals
30 July 2026
2026 Fibronectin glomerulopathy indication strategy covering epidemiology, FN1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Thin basement membrane nephropathy Indication Strategy Report 2026: COL4A3, Trials and Deals
30 July 2026
2026 Thin basement membrane nephropathy indication strategy covering epidemiology, COL4A3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Cystinosis Indication Strategy Report 2026: CTNS, Trials and Deals
30 July 2026
2026 Cystinosis indication strategy covering epidemiology, CTNS biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Lowe syndrome Indication Strategy Report 2026: OCRL, Trials and Deals
30 July 2026
2026 Lowe syndrome indication strategy covering epidemiology, OCRL biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Autosomal recessive Alport syndrome Indication Strategy Report 2026: COL4A3, Trials and Deals
30 July 2026
2026 Autosomal recessive Alport syndrome indication strategy covering epidemiology, COL4A3 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Alport syndrome X-linked Indication Strategy Report 2026: COL4A5, Trials and Deals
30 July 2026
2026 Alport syndrome X-linked indication strategy covering epidemiology, COL4A5 biology, active trials, transactions, unmet need, competition and market…